Breaking News Instant updates and real-time market news.

FIT

Fitbit

$5.86

0.06 (1.03%)

, HUM

Humana

$336.41

0.57 (0.17%)

10:31
09/19/18
09/19
10:31
09/19/18
10:31

Fitbit in focus amid expanded strategic partnership with Humana

Shares of smartband and smartwatch maker Fitbit (FIT) are higher after the company announced it is expanding its strategic partnership with Humana (HUM) to drive healthy habits and manage chronic disease. STRATEGIC PARTNERSHIP EXPANSION: On Wednesday, Fitbit and Humana announced that they are expanding their partnership to help members adopt and implement healthy behaviors to help prevent and manage chronic conditions. Humana has selected Fitbit Care as a preferred health coaching solution for Humana's employer group segment and through this partnership, over five million Humana members will have the potential to access Fitbit wellness solutions or health coaching. Fitbit Care is a connected health platform, launched today, that combines health coaching and virtual care, Fitbit's wearable devices and self-tracking and personalized digital interventions. The Fitbit Care health coaching solution has coaches working with participants to create personalized care plans and connecting with members through multiple channels that include in-app communications, phone and in-person meetings. Users who already have health coaches can connect with them through the platform or they can opt for "a fully wrapped solution" where the company provides the technology and wellness advice. Fitbit and Humana also announced the availability of the Humana Go365 clock face on Fitbit Versa and Fitbit Ionic devices, making members' Go365 activity data accessible right from the wrist. EXECUTIVE COMMENTARY: "Working with Fitbit, we have been able to provide our members with wearable devices, data and insights they can use to achieve their best health and wellness. By adding Fitbit Care's new health coaching capabilities, we can offer even more personalized, meaningful support to our members who are focused on specific health goals, such as smoking cessation or weight loss, or the management or prevention of chronic conditions," said Jeff Reid, Humana's senior vice president of Wellness Solutions. "Fitbit's intuitive technology and human coaches are powerful tools to engage and motivate members, creating more frequent, convenient touch-points that support our members beyond the walls of a doctor's office." Adam Pelligrini, general manager of Fitbit Health Solutions, said, "We're already seeing proof points that the solutions we're building are taking hold and are resonating with our health plan and employer customers." Pelligrini added Fitbit already works with over 100 health plans and its health solutions business unit currently represents less than 10% of the company's overall revenue. WHAT'S NOTABLE: Shares of Fitbit fell on September 12 after Apple (AAPL) unveiled its new Watch Series 4 at its product event. The device features a larger display, new user interface, digital crown with haptics, faster performance, louder speaker and electrical heart sensor with electrocardiogram app and an optical heart sensor. In addition, the company said it received Food and Drug Administration approval for the built-in ECG scanner and it is the first over-the-counter ECG product. Following the fall, Morgan Stanley analyst Yuuji Anderson told investors that he believes the drop "rightly reflects" concerns over the pace of software and sensor improvements at Fitbit. However, the analyst added that he is more concerned that the functionalities of Fitbit's Versa and Charge 3 are not sufficiently differentiated to avoid cannibalization and their aggregate demand will not sufficiently offset legacy product declines. 'SIGNIFICANT EVOLUTION:' Craig-Hallum analyst Alex Fuhrman called Fitbit's Fitbit Care launch a "significant evolution" in the company's strategy to add value as a healthcare partner and to increase its recurring revenues. He also views the concurrent Humana (HUM) partnership announcement as evidence of the strong market demand for companies and healthcare providers to partner with Fitbit and integrate its data into users' other care plans. PRICE ACTION: Fitbit is up 2.1% to $5.92 in morning trading.

FIT

Fitbit

$5.86

0.06 (1.03%)

HUM

Humana

$336.41

0.57 (0.17%)

AAPL

Apple

$215.54

-2.7 (-1.24%)

  • 27

    Sep

  • 28

    Sep

FIT Fitbit
$5.86

0.06 (1.03%)

09/07/18
ROTH
09/07/18
NO CHANGE
Target $8
ROTH
Buy
Roth positive on Fitbit's second half prospects after meeting with management
Roth Capital analyst Scott Searle said that after meeting with Fitbit management he is positive on its prospects for the second half of the year given the introduction of the Charge 3 fitness tracker and continued strength in smartwatches. The analyst, who continues to think the potential value of Fitbit's digital therapeutics model is underappreciated by the Street, keeps an Buy rating and $8 price target on Fitbit shares.
09/13/18
DADA
09/13/18
NO CHANGE
Target $265
DADA
Buy
Apple new product lineup increases near term sales confidence, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $265 price target on Apple (AAPL) after its product re-fresh yesterday, saying the event increases his confidence in the company "meeting or exceeding" consensus for sales in the near term. The analyst believes that the starting price points for the iPhone XS and iPhone XS Max should boost Apple's average selling prices and allow the company to "bear financial fruit" of the updated lineup without having to increase unit sales. As part of his broader research note, Forte also keeps his Neutral rating on Fitbit (FIT), saying the cost-conscious consumers will still purchase its Versa smartwatch rather than opt for the more expensive Apple Watch. The analyst is also positive on Zagg (ZAGG), maintaining his Buy rating and $20 price target on expectation that consumers will want to protect their expensive smartwatch products with the company's screen protectors and cases.
09/13/18
MSCO
09/13/18
NO CHANGE
Target $4
MSCO
Underweight
Fitbit drop after Apple reveal 'righlty reflects' concerns, says Morgan Stanley
Morgan Stanley analyst Yuuji Anderson said Fitbit's (FIT) 7% drop yesterday was likely a reaction to Apple (AAPL) unveiling a Series 4 Watch with sensors and an app that can help detect atrial fibrillation, which is a use case Fitbit is also pursuing. Anderson believes the drop in Fitbit shares "n rightly reflects" concerns over the pace of software and sensor improvements at Fitbit, but adds that he is more concerned that the functionalities of the Versa and Charge 3 are not sufficiently differentiated to avoid cannibalization and their aggregate demand will not sufficiently offset legacy product declines. Anderson keeps an Underweight rating on Fitbit shares with a $4 price target.
09/19/18
CHLM
09/19/18
NO CHANGE
Target $10
CHLM
Buy
Fitbit launch of 'Care' service a significant evolution, says Craig-Hallum
Craig-Hallum analyst Alex Fuhrman called Fitbit's (FIT) launch of its new enterprise-level service called "Fitbit Care" a "significant evolution" in the company's strategy to add value as a healthcare partner and to increase its recurring revenues. He also views the concurrent Humana (HUM) partnership announcement as evidence of the strong market demand for companies and healthcare providers to partner with Fitbit and integrate its data into users' other care plans. Fuhrman reiterates his Buy rating and $10 price target on Fitbit shares.
HUM Humana
$336.41

0.57 (0.17%)

09/17/18
COWN
09/17/18
INITIATION
Target $373
COWN
Market Perform
Humana initiated with a Market Perform at Cowen
Cowen analyst Charles Ryhee initiated Humana with a Market Perform rating and $373 price target. He believes its current valuation reflects a takeout premium, which he does not think will get realized.
09/13/18
LEHM
09/13/18
INITIATION
Target $370
LEHM
Overweight
Barclays sees favorable Medicare Advantage outlook, starts Humana at Overweight
Barclays analyst Steve Valiquette initiated coverage of Humana (HUM) with an Overweight rating and $370 price target. The fundamental Medicare Advantage outlook is the strongest it has been since pre-Affordable Care Act levels "thanks to a number of industry tailwinds brought about by the Republican administration," Valiquette tells investors in a research note. These include higher Medicare reimbursement, corporate tax reform, and 2019 health insurance fund suspension, the analyst says. He believes Humana will be able to deliver on its low-to-mid-teens annual adjusted earnings target through at least 2021. Valiquette this morning also initiated coverage of Cerner with an Equal Weight rating and $70 price target. The company's 7%-12% revenue growth outlook relies on the ramp-up of newer products, the analyst contends.
09/19/18
RHCO
09/19/18
NO CHANGE
Target $380
RHCO
Hold
Humana price target raised to $380 from $350 at SunTrust
SunTrust analyst David MacDonald raised his price target on Humana to $380 after his "upbeat" meetings with its management. The analyst says the discussion focused on "strong core trends, key areas of growth, broad consumer-centric capabilities and strong momentum" heading into 2019. MacDonald also cites Humana's "attractive opportunity" around the increasingly apparent Medicare-Medicaid synergies for the Dual Eligible Special Needs Plans as well as its plentiful capital deployment opportunities. The analyst keeps his Hold rating on the shares however, noting that Humana's risk-reward is "balanced".
AAPL Apple
$215.54

-2.7 (-1.24%)

09/14/18
MONN
09/14/18
NO CHANGE
Target $300
MONN
Buy
Apple pprice target raised to $300 from $275 at Monness Crespi
Monness Crespi analyst Brian White raised Buy rated Apple's price target to $300 from $275 based on new iPhone and Apple Watch innovations. White said shares trade at just 15x earnings, ex-cash, and believes new innovations will continue to drive the iPhone cycle with favorable ASPs, and looks for continued momentum in Services.
09/17/18
RSBL
09/17/18
NO CHANGE
RSBL
Buy
Apple iPhone XS and XS Max preorders down versus iPhone X,says Rosenblatt
Rosenblatt analyst Jun Zhang believes Apple iPhone XS and XS Max preorders are approximately 10M units in the first three days based on current wait times of about 1-2 weeks, compared to iPhone X preorders last year of about 12M units in the first three days, with lead times of 3-5 weeks. Zhang expects 35-36M iPhone XS and XS Max units in calendar Q3 and Q4, below what he believes iPhone X produced of 36M units in Q3 and Q4 of last year.
09/18/18
RBCM
09/18/18
NO CHANGE
Target $240
RBCM
Outperform
Apple's iPhone average selling prices expected to grow, says RBC Capital
cRBC Capital analyst Amit Daryanani kept his Outperform rating and $240 price target on Apple after its product event last week, saying that the new iPhone line-up should result in higher average selling price, or ASP, metric for 2018 in spite of the "difficult comps from iPhone X cycle". The analyst "conservatively" estimates ASPs to rise in the low single digits assuming the XR version is the more popular product. Daryanani adds that in his upside scenario where iPhone XsMax is the more popular SKU, ASPs may see a double digit benefit.
09/19/18
LOOP
09/19/18
NO CHANGE
Target $256
LOOP
Buy
Apple offers 'handful of catalysts' and 'stable' valuation, says Loop Capital
Loop Capital analyst Ananda Baruah kept his Buy rating and $256 price target on Apple, saying his FY18 and FY19 EPS estimates of $12.60 and $14.49 are above those of consensus at $12.20 and $13.93 respectively. The analyst cites catalysts such as the 1st week iPhone pre-order data expected this week and does not agree with his competitors' views that those figures may be soft. The analyst also sees Apple's $100B stock buyback supporting the shares and views the company's valuation as "stable" at 15-16-times forward earnings - a multiple he expects to be sustained on iPhone sales mix, momentum of Services segment, and the capital program.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
06/18/19
06/18
15:16
06/18/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$7.71

0.09 (1.18%)

15:15
06/18/19
06/18
15:15
06/18/19
15:15
Options
McDermott put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$27.59

0.64 (2.37%)

15:12
06/18/19
06/18
15:12
06/18/19
15:12
Hot Stocks
Fifth Third jumps almost 2.5% after raising dividend, new 100M buyback »

Shares of Fifth Third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

JBL

Jabil

$27.45

0.655 (2.44%)

15:04
06/18/19
06/18
15:04
06/18/19
15:04
Options
Jabil Circuit options imply 11.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

14:55
06/18/19
06/18
14:55
06/18/19
14:55
General news
FOMC forecast preview: »

FOMC forecast preview:…

APC

Anadarko

$70.00

0.21 (0.30%)

14:52
06/18/19
06/18
14:52
06/18/19
14:52
Periodicals
Anadarko gives go-ahead on $20B LNG export project in Mozambique, Reuters says »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSP

E.W. Scripps

$15.02

0.01 (0.07%)

, CBS

CBS

$49.38

0.22 (0.45%)

14:50
06/18/19
06/18
14:50
06/18/19
14:50
Hot Stocks
E.W. Scripps reports consent decree to settle DOJ civil case »

In a regulatory filing,…

SSP

E.W. Scripps

$15.02

0.01 (0.07%)

CBS

CBS

$49.38

0.22 (0.45%)

FOXA

Fox Corp.

$36.59

0.44 (1.22%)

FOX

Fox Corp.

$36.23

0.44 (1.23%)

TGNA

Tegna

$15.09

0.22 (1.48%)

SBGI

Sinclair Broadcast

$53.51

0.01 (0.02%)

NXST

Nexstar

$102.72

2.31 (2.30%)

MDP

Meredith

$53.04

0.88 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Jun

  • 06

    Aug

  • 08

    Aug

  • 13

    Nov

WFC

Wells Fargo

$46.25

0.99 (2.19%)

, GS

Goldman Sachs

$195.72

4.98 (2.61%)

14:50
06/18/19
06/18
14:50
06/18/19
14:50
Periodicals
Wells Fargo dismissed from VRDO lawsuit, Reuters reports »

Wells Fargo & Co…

WFC

Wells Fargo

$46.25

0.99 (2.19%)

GS

Goldman Sachs

$195.72

4.98 (2.61%)

JPM

JPMorgan

$111.21

2.01 (1.84%)

BAC

Bank of America

$28.72

0.79 (2.83%)

BCS

Barclays

$7.59

0.09 (1.20%)

C

Citi

$68.12

1.59 (2.39%)

RY

Royal Bank of Canada

$78.69

1.45 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

  • 13

    Jul

  • 13

    Jul

  • 15

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 13

    Aug

  • 21

    Aug

  • 12

    Oct

ADBE

Adobe

$278.26

2.67 (0.97%)

14:49
06/18/19
06/18
14:49
06/18/19
14:49
Options
Adobe options imply 5.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

RARX

RA Pharmaceuticals

$22.36

-0.38 (-1.67%)

14:48
06/18/19
06/18
14:48
06/18/19
14:48
Recommendations
RA Pharmaceuticals analyst commentary  »

RA Pharmaceuticals price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FITB

Fifth Third

$27.53

0.58 (2.15%)

14:46
06/18/19
06/18
14:46
06/18/19
14:46
Hot Stocks
Fifth Third boosts quarterly dividend 9% to 24c »

Fifth Third Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

MAS

Masco

$38.12

0.22 (0.58%)

14:42
06/18/19
06/18
14:42
06/18/19
14:42
Recommendations
Masco analyst commentary  »

Masco sale of cyclical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$31.69

0.82 (2.66%)

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Options
Skechers call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLT

Poly

$44.03

0.98 (2.28%)

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Conference/Events
Poly participates in an investor webinar with Northland Capital Markets »

Northland Capital Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

  • 28

    Jun

  • 13

    Nov

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

GIII

G-III Apparel

$26.38

0.71 (2.77%)

14:18
06/18/19
06/18
14:18
06/18/19
14:18
Hot Stocks
G-III Apparel up 6% after CEO buys over $1M worth of shares »

G-III Apparel Group CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/18/19
06/18
14:17
06/18/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/18/19
06/18
14:16
06/18/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPW

DPW Holdings

$0.14

-0.003 (-2.13%)

14:15
06/18/19
06/18
14:15
06/18/19
14:15
Hot Stocks
Breaking Hot Stocks news story on DPW Holdings  »

Digital Power trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

14:06
06/18/19
06/18
14:06
06/18/19
14:06
Periodicals
USTR says China tariffs only recourse given dialogue has failed, Reuters says »

U.S. Trade Representative…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$27.10

0.67 (2.54%)

14:05
06/18/19
06/18
14:05
06/18/19
14:05
Options
Arrowhead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

DPW

DPW Holdings

$0.14

-0.003 (-2.13%)

14:01
06/18/19
06/18
14:01
06/18/19
14:01
Hot Stocks
DPW Holdings announces deal with senior lender to refinance outstanding debt »

DPW Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

CMCSA

Comcast

$43.10

0.54 (1.27%)

, CHTR

Charter

$396.65

2.64 (0.67%)

13:58
06/18/19
06/18
13:58
06/18/19
13:58
Hot Stocks
Comcast says Charter, Cox join 'On Addressability' initiative »

Comcast Advertising, the…

CMCSA

Comcast

$43.10

0.54 (1.27%)

CHTR

Charter

$396.65

2.64 (0.67%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CVS

CVS Health

$54.84

0.32 (0.59%)

13:55
06/18/19
06/18
13:55
06/18/19
13:55
Conference/Events
CVS Health participates in a conference call with JPMorgan »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

GOOG

Alphabet

$1,107.00

14.75 (1.35%)

, GOOGL

Alphabet Class A

$1,110.00

17.29 (1.58%)

13:54
06/18/19
06/18
13:54
06/18/19
13:54
Periodicals
Google tells Bloomberg issues with calendar resolved »

Google said in a…

GOOG

Alphabet

$1,107.00

14.75 (1.35%)

GOOGL

Alphabet Class A

$1,110.00

17.29 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.